Cyrano Therapeutics Achieves Enrollment Milestone in Phase 2 Trial
Data from the trial is anticipated in late 2025, marking a pivotal moment for post-viral smell loss therapy.
Cyrano Therapeutics, a prominent clinical-stage regenerative medicine company focused on innovative treatments for smell loss, has proudly announced the completion of patient enrollment in its Phase 2 FLAVOR trial. This comprehensive study is designed to assess CYR-064, a unique soft-mist nasal spray targeting post-viral hyposmia, which translates to the loss of smell following viral infections.
This carefully structured trial has enrolled a total of 150 patients, who will be observed across 14 designated clinical sites. The primary goal is to evaluate the safety, tolerability, and overall efficacy of CYR-064 when compared to a placebo over a six-month span. Post-viral hyposmia is a pervasive sensory condition affecting an estimated 60 million individuals in the United States, Europe, Japan, and countless others globally. Remarkably, despite its prevalence, no FDA-approved treatments currently exist for this condition.
Rick Geoffrion, the President and CEO of Cyrano Therapeutics, expressed his enthusiasm, stating, "Completing enrollment for our FLAVOR trial represents a monumental step forward in our dedication to introducing the first pharmaceutical solution for post-viral smell loss. We're extremely thankful to the patients and investigators who have played vital roles in advancing this crucial research. The data we will gather from this trial is expected to significantly shape the future development of CYR-064."
CYR-064 stands out as a proprietary intranasal formulation that includes a broad-spectrum phosphodiesterase (PDE) inhibitor. This formulation aims to enhance the excitability of olfactory neurons, which are critical for restoring the sense of smell. A noteworthy element of CYR-064's delivery system is the 3K pump from Ursatec, integrated with state-of-the-art Resyca soft mist spray technology. This advanced mechanism guarantees the accurate, targeted delivery of the medication to the olfactory region, optimizing the potential therapeutic effects while ensuring the simplicity of use for patients.
Mas Takashima, MD FACS, who serves as the principal investigator for the FLAVOR trial and is also the Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at Houston Methodist Hospital, shared his insights: "Reaching the enrollment target for our FLAVOR trial is a significant achievement in our mission to develop a viable treatment option for those suffering from post-viral hyposmia. The dedication shown by participating patients is encouraging, and we eagerly await the trial results to substantiate the potential of CYR-064 as an evidence-based solution for this condition."
About Cyrano Therapeutics
Cyrano Therapeutics is a dynamic, venture-backed clinical stage regenerative medicine company dedicated to creating solutions for individuals affected by the loss of their sense of smell and taste. Their commitment to advancing therapeutic options results in persistent research and development efforts, promising hope for many.
Media Contact:
Tiberend Strategic Advisors, Inc.
Eric Reiss
Frequently Asked Questions
What is CYR-064 and its purpose?
CYR-064 is a soft-mist nasal spray developed to treat loss of smell following viral infections, aiming to enhance olfactory neuron function.
Why is the FLAVOR trial significant?
The FLAVOR trial is crucial as it evaluates the first potential pharmaceutical treatment for post-viral hyposmia, a condition with no FDA-approved therapies.
How many patients are enrolled in the Phase 2 trial?
A total of 150 patients have been enrolled at 14 clinical sites for the FLAVOR trial.
When are the results of the trial expected?
Data from the trial is anticipated in the fourth quarter of 2025.
Who is leading the FLAVOR trial?
The trial is led by Dr. Mas Takashima, a prominent figure in the field of otolaryngology.
